Ian A. Cook
Chief Tech/Sci/R&D Officer at NeuroSigma, Inc.
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| David Hayes | M | 69 |
NeuroSigma, Inc.
 NeuroSigma, Inc. Medical SpecialtiesHealth Technology NeuroSigma, Inc. operates as a life sciences company which develops bioelectronic technologies to treat major neurological and neuropsychiatric disorders such as epilepsy and depression. Its non-invasive external trigeminal nerve stimulation system (eTNS) employs trigeminal nerve stimulation, or TNS, as adjunctive therapy for drug-resistant epilepsy and major depressive disorder. The company was founded by Leon Ekchian in March 2008 and is headquartered in Los Angeles, CA. | 10 years |
| Leon Ekchian | M | 67 |
NeuroSigma, Inc.
NeuroSigma, Inc. Medical SpecialtiesHealth Technology NeuroSigma, Inc. operates as a life sciences company which develops bioelectronic technologies to treat major neurological and neuropsychiatric disorders such as epilepsy and depression. Its non-invasive external trigeminal nerve stimulation system (eTNS) employs trigeminal nerve stimulation, or TNS, as adjunctive therapy for drug-resistant epilepsy and major depressive disorder. The company was founded by Leon Ekchian in March 2008 and is headquartered in Los Angeles, CA. | 16 years |
| Colin Kealey | M | - |
NeuroSigma, Inc.
NeuroSigma, Inc. Medical SpecialtiesHealth Technology NeuroSigma, Inc. operates as a life sciences company which develops bioelectronic technologies to treat major neurological and neuropsychiatric disorders such as epilepsy and depression. Its non-invasive external trigeminal nerve stimulation system (eTNS) employs trigeminal nerve stimulation, or TNS, as adjunctive therapy for drug-resistant epilepsy and major depressive disorder. The company was founded by Leon Ekchian in March 2008 and is headquartered in Los Angeles, CA. | - |
| Linda Liau | M | 57 |
David Geffen School of Medicine
| - |
| Andrew Woo | M | 61 |
David Geffen School of Medicine
| - |
| Thomas Paschall | M | - |
NeuroSigma, Inc.
NeuroSigma, Inc. Medical SpecialtiesHealth Technology NeuroSigma, Inc. operates as a life sciences company which develops bioelectronic technologies to treat major neurological and neuropsychiatric disorders such as epilepsy and depression. Its non-invasive external trigeminal nerve stimulation system (eTNS) employs trigeminal nerve stimulation, or TNS, as adjunctive therapy for drug-resistant epilepsy and major depressive disorder. The company was founded by Leon Ekchian in March 2008 and is headquartered in Los Angeles, CA. | - |
| Heather Dale Jones | M | - |
David Geffen School of Medicine
| - |
| Jonathan Corren | M | - |
David Geffen School of Medicine
| - |
| Chun Kit Ho | M | 47 |
David Geffen School of Medicine
| - |
| Anna M. Wu | M | - |
David Geffen School of Medicine
| - |
| Cathleen Bairey-Merz | M | 68 |
David Geffen School of Medicine
| - |
| Richard David | M | 64 |
David Geffen School of Medicine
| - |
| Perry Shieh | M | - |
David Geffen School of Medicine
| - |
| Enrique Lavernia | M | - |
Henry Samueli School of Engineering & Applied Science
| - |
| Dennis Joseph Slamon | M | 75 |
David Geffen School of Medicine
| - |
| Frederick C. Beddingfield | M | 59 |
David Geffen School of Medicine
| 21 years |
| Christopher M. DeGiorgio | M | - |
NeuroSigma, Inc.
NeuroSigma, Inc. Medical SpecialtiesHealth Technology NeuroSigma, Inc. operates as a life sciences company which develops bioelectronic technologies to treat major neurological and neuropsychiatric disorders such as epilepsy and depression. Its non-invasive external trigeminal nerve stimulation system (eTNS) employs trigeminal nerve stimulation, or TNS, as adjunctive therapy for drug-resistant epilepsy and major depressive disorder. The company was founded by Leon Ekchian in March 2008 and is headquartered in Los Angeles, CA. | 12 years |
| Kirk Calhoun | M | 80 |
NeuroSigma, Inc.
NeuroSigma, Inc. Medical SpecialtiesHealth Technology NeuroSigma, Inc. operates as a life sciences company which develops bioelectronic technologies to treat major neurological and neuropsychiatric disorders such as epilepsy and depression. Its non-invasive external trigeminal nerve stimulation system (eTNS) employs trigeminal nerve stimulation, or TNS, as adjunctive therapy for drug-resistant epilepsy and major depressive disorder. The company was founded by Leon Ekchian in March 2008 and is headquartered in Los Angeles, CA. | - |
| David L. Hill | M | 73 |
David Geffen School of Medicine
| - |
| Robert E. Reiter | M | - |
David Geffen School of Medicine
| - |
| Aimee Weisner | F | 55 |
NeuroSigma, Inc.
NeuroSigma, Inc. Medical SpecialtiesHealth Technology NeuroSigma, Inc. operates as a life sciences company which develops bioelectronic technologies to treat major neurological and neuropsychiatric disorders such as epilepsy and depression. Its non-invasive external trigeminal nerve stimulation system (eTNS) employs trigeminal nerve stimulation, or TNS, as adjunctive therapy for drug-resistant epilepsy and major depressive disorder. The company was founded by Leon Ekchian in March 2008 and is headquartered in Los Angeles, CA. | 10 years |
| Arie Belldegrun | M | 74 |
David Geffen School of Medicine
| 24 years |
| Allen Nissenson | M | 77 |
David Geffen School of Medicine
| 47 years |
| Robert Sellers | M | - |
NeuroSigma, Inc.
NeuroSigma, Inc. Medical SpecialtiesHealth Technology NeuroSigma, Inc. operates as a life sciences company which develops bioelectronic technologies to treat major neurological and neuropsychiatric disorders such as epilepsy and depression. Its non-invasive external trigeminal nerve stimulation system (eTNS) employs trigeminal nerve stimulation, or TNS, as adjunctive therapy for drug-resistant epilepsy and major depressive disorder. The company was founded by Leon Ekchian in March 2008 and is headquartered in Los Angeles, CA. | - |
| Lodwrick Monroe Cook | M | 95 |
NeuroSigma, Inc.
NeuroSigma, Inc. Medical SpecialtiesHealth Technology NeuroSigma, Inc. operates as a life sciences company which develops bioelectronic technologies to treat major neurological and neuropsychiatric disorders such as epilepsy and depression. Its non-invasive external trigeminal nerve stimulation system (eTNS) employs trigeminal nerve stimulation, or TNS, as adjunctive therapy for drug-resistant epilepsy and major depressive disorder. The company was founded by Leon Ekchian in March 2008 and is headquartered in Los Angeles, CA. | - |
| Julia Gouw | F | 64 |
David Geffen School of Medicine
| - |
| Sanford R. Climan | M | 68 |
Semel Institute For Neuroscience & Human Behavior
| - |
| Scott Weingarten | M | - |
David Geffen School of Medicine
| - |
| Linda M. Rosenstock | M | 73 |
David Geffen School of Medicine
| 24 years |
| James Hindman | M | 63 |
NeuroSigma, Inc.
NeuroSigma, Inc. Medical SpecialtiesHealth Technology NeuroSigma, Inc. operates as a life sciences company which develops bioelectronic technologies to treat major neurological and neuropsychiatric disorders such as epilepsy and depression. Its non-invasive external trigeminal nerve stimulation system (eTNS) employs trigeminal nerve stimulation, or TNS, as adjunctive therapy for drug-resistant epilepsy and major depressive disorder. The company was founded by Leon Ekchian in March 2008 and is headquartered in Los Angeles, CA. | 10 years |
| Jeffery F. Miller | M | - |
David Geffen School of Medicine
| - |
| Robert Figlin | M | - |
David Geffen School of Medicine
| - |
| John Schauerman | M | 67 |
Henry Samueli School of Engineering & Applied Science
| - |
| Yutaka Niihara | M | 65 |
David Geffen School of Medicine
| - |
| Owen Witte | M | 74 |
David Geffen School of Medicine
| - |
| Matthew Freeby | M | - |
David Geffen School of Medicine
| - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Carl Adams | M | 54 |
NeuroSigma, Inc.
NeuroSigma, Inc. Medical SpecialtiesHealth Technology NeuroSigma, Inc. operates as a life sciences company which develops bioelectronic technologies to treat major neurological and neuropsychiatric disorders such as epilepsy and depression. Its non-invasive external trigeminal nerve stimulation system (eTNS) employs trigeminal nerve stimulation, or TNS, as adjunctive therapy for drug-resistant epilepsy and major depressive disorder. The company was founded by Leon Ekchian in March 2008 and is headquartered in Los Angeles, CA. | - |
| William G. Ouchi | M | 80 |
David Geffen School of Medicine
| - |
| Roy Doumani | M | 89 |
David Geffen School of Medicine
| 15 years |
| Rajeev Madhavan | M | 58 |
Henry Samueli School of Engineering & Applied Science
| 13 years |
| Louis J. Ignarro | M | 83 |
David Geffen School of Medicine
| 28 years |
| Gregory F. Brooks | M | - |
NeuroSigma, Inc.
NeuroSigma, Inc. Medical SpecialtiesHealth Technology NeuroSigma, Inc. operates as a life sciences company which develops bioelectronic technologies to treat major neurological and neuropsychiatric disorders such as epilepsy and depression. Its non-invasive external trigeminal nerve stimulation system (eTNS) employs trigeminal nerve stimulation, or TNS, as adjunctive therapy for drug-resistant epilepsy and major depressive disorder. The company was founded by Leon Ekchian in March 2008 and is headquartered in Los Angeles, CA. | - |
| David Sherman | M | - |
David Geffen School of Medicine
| 6 years |
| Marti Arvin | F | - |
David Geffen School of Medicine
| 5 years |
| Hong Wu | M | 66 |
David Geffen School of Medicine
| 17 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 45 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Ian A. Cook
- Personal Network
